• Something wrong with this record ?

Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial

A. Arenas-Pinto, B. Grund, S. Sharma, E. Martinez, N. Cummins, J. Fox, KL. Klingman, D. Sedlacek, S. Collins, PM. Flynn, WM. Chasanov, E. Kedem, C. Katlama, J. Sierra-Madero, C. Afonso, P. Brouwers, DA. Cooper, INSIGHT START study group,

. 2018 ; 67 (3) : 420-429. [pub] 20180718

Language English Country United States

Document type Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19045528

Grant support
UM1 AI068641 NIAID NIH HHS - United States
UM1 AI120197 NIAID NIH HHS - United States
Medical Research Council - United Kingdom
Department of Health - United Kingdom

Background: Randomized trials have shown increased risk of suicidality associated with efavirenz (EFV). The START (Strategic Timing of Antiretroviral Treatment) trial randomized treatment-naive human immunodeficiency virus (HIV)-positive adults with high CD4 cell counts to immediate vs deferred antiretroviral therapy (ART). Methods: The initial ART regimen was selected prior to randomization (prespecified). We compared the incidence of suicidal and self-injurious behaviours (suicidal behavior) between the immediate vs deferred ART groups using proportional hazards models, separately for those with EFV and other prespecified regimens, by intention to treat, and after censoring participants in the deferred arm at ART initiation. Results: Of 4684 participants, 271 (5.8%) had a prior psychiatric diagnosis. EFV was prespecified for 3515 participants (75%), less often in those with psychiatric diagnoses (40%) than without (77%). While the overall intention-to-treat comparison showed no difference in suicidal behavior between arms (hazard ratio [HR], 1.07, P = .81), subgroup analyses suggest that initiation of EFV, but not other ART, is associated with increased risk of suicidal behavior. When censoring follow-up at ART initiation in the deferred group, the immediate vs deferred HR among those who were prespecified EFV was 3.31 (P = .03) and 1.04 (P = .93) among those with other prespecified ART; (P = .07 for interaction). In the immediate group, the risk was higher among those with prior psychiatric diagnoses, regardless of prespecified treatment group. Conclusions: Participants who used EFV in the immediate ART group had increased risk of suicidal behavior compared with ART-naive controls. Those with prior psychiatric diagnoses were at higher risk.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045528
003      
CZ-PrNML
005      
20200113135037.0
007      
ta
008      
200109s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1093/cid/ciy051 $2 doi
035    __
$a (PubMed)29538636
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Arenas-Pinto, Alejandro $u Medical Research Council Clinical Trials Unit, University College London, United Kingdom.
245    10
$a Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial / $c A. Arenas-Pinto, B. Grund, S. Sharma, E. Martinez, N. Cummins, J. Fox, KL. Klingman, D. Sedlacek, S. Collins, PM. Flynn, WM. Chasanov, E. Kedem, C. Katlama, J. Sierra-Madero, C. Afonso, P. Brouwers, DA. Cooper, INSIGHT START study group,
520    9_
$a Background: Randomized trials have shown increased risk of suicidality associated with efavirenz (EFV). The START (Strategic Timing of Antiretroviral Treatment) trial randomized treatment-naive human immunodeficiency virus (HIV)-positive adults with high CD4 cell counts to immediate vs deferred antiretroviral therapy (ART). Methods: The initial ART regimen was selected prior to randomization (prespecified). We compared the incidence of suicidal and self-injurious behaviours (suicidal behavior) between the immediate vs deferred ART groups using proportional hazards models, separately for those with EFV and other prespecified regimens, by intention to treat, and after censoring participants in the deferred arm at ART initiation. Results: Of 4684 participants, 271 (5.8%) had a prior psychiatric diagnosis. EFV was prespecified for 3515 participants (75%), less often in those with psychiatric diagnoses (40%) than without (77%). While the overall intention-to-treat comparison showed no difference in suicidal behavior between arms (hazard ratio [HR], 1.07, P = .81), subgroup analyses suggest that initiation of EFV, but not other ART, is associated with increased risk of suicidal behavior. When censoring follow-up at ART initiation in the deferred group, the immediate vs deferred HR among those who were prespecified EFV was 3.31 (P = .03) and 1.04 (P = .93) among those with other prespecified ART; (P = .07 for interaction). In the immediate group, the risk was higher among those with prior psychiatric diagnoses, regardless of prespecified treatment group. Conclusions: Participants who used EFV in the immediate ART group had increased risk of suicidal behavior compared with ART-naive controls. Those with prior psychiatric diagnoses were at higher risk.
650    _2
$a dospělí $7 D000328
650    _2
$a látky proti HIV $x škodlivé účinky $7 D019380
650    _2
$a vysoce aktivní antiretrovirová terapie $7 D023241
650    _2
$a benzoxaziny $x škodlivé účinky $7 D048588
650    _2
$a počet CD4 lymfocytů $7 D018791
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a HIV infekce $x komplikace $x farmakoterapie $7 D015658
650    _2
$a HIV séropozitivita $x farmakoterapie $7 D006679
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a chování sebezraňující $x epidemiologie $7 D016728
650    12
$a sebevražda $7 D013405
650    _2
$a virová nálož $7 D019562
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Grund, Birgit $u School of Statistics, Minneapolis.
700    1_
$a Sharma, Shweta $u Division of Biostatistics, University of Minnesota, Minneapolis.
700    1_
$a Martinez, Esteban $u Hospital Clinic, Barcelona, Spain.
700    1_
$a Cummins, Nathan $u Mayo Clinic, Rochester, Minnesota.
700    1_
$a Fox, Julie $u Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom.
700    1_
$a Klingman, Karin L $u Division of AIDS, National Institute of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
700    1_
$a Sedlacek, Dalibor $u University Hospital Plzen, Czech Republic.
700    1_
$a Collins, Simon $u HIV i-Base, London, United Kingdom.
700    1_
$a Flynn, Patricia M $u St. Jude Children's Research Hospital, Memphis, Tennessee.
700    1_
$a Chasanov, William M $u Cooper University Hospital, Camden, New Jersey.
700    1_
$a Kedem, Eynat $u Clinical Immunology Unit, Rambam Health Care Center, Haifa, Israel.
700    1_
$a Katlama, Christine $u Hospitalier Pitié-Salpétrière, Paris, France.
700    1_
$a Sierra-Madero, Juan $u Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, México.
700    1_
$a Afonso, Claudia $u Hospital de Santa Maria, Lisbon, Portugal.
700    1_
$a Brouwers, Pim $u Division of AIDS, National Institute of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
700    1_
$a Cooper, David A $u The Kirby Institute, University of New South Wales, Sydney, Australia.
710    2_
$a INSIGHT START study group
773    0_
$w MED00001133 $t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America $x 1537-6591 $g Roč. 67, č. 3 (2018), s. 420-429
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29538636 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113135409 $b ABA008
999    __
$a ok $b bmc $g 1483796 $s 1084201
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 67 $c 3 $d 420-429 $e 20180718 $i 1537-6591 $m Clinical infectious diseases $n Clin Infect Dis $x MED00001133
GRA    __
$a UM1 AI068641 $p NIAID NIH HHS $2 United States
GRA    __
$a UM1 AI120197 $p NIAID NIH HHS $2 United States
GRA    __
$p Medical Research Council $2 United Kingdom
GRA    __
$p Department of Health $2 United Kingdom
LZP    __
$a Pubmed-20200109

Find record

Citation metrics

Archiving options